AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
vaborbactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 5253 | 1360457-46-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Vaborbactam is a non-suicidal beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases such as Klebsiella pneumoniae carbapenemase (KPC). Vaborbactam does not have any antibacterial activity. Vaborbactam does not decrease the activity of meropenem against meropenem-susceptible organisms.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 3 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.29 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.94 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.67 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.34 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 5.26 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.556 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.841 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 1.514 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.304 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 61.860 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 57.260 | % | High | 1 |
| herg | hERG pIC50 | 4.347 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.811 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.289 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 54.930 | % | High | 1 |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.705 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 2.606 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 77.090 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.796 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 64.270 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.233 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 85.570 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 57.770 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 914.113 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 29, 2017 | FDA | REMPEX PHARMS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DH52 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Carbapenems |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| FDA MoA | N0000000202 | beta Lactamase Inhibitors |
| FDA EPC | N0000175930 | beta Lactamase Inhibitor |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J01DH Carbapenems 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Urinary tract infection caused by Klebsiella | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.76 | acidic |
| pKa2 | 9.79 | acidic |
| pKa3 | 13.85 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 10183034 | Aug. 8, 2031 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 10561675 | Aug. 8, 2031 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 11007206 | Aug. 8, 2031 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 9694025 | Aug. 8, 2031 | TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 12478606 | Jan. 8, 2038 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 11376237 | April 6, 2039 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | 12533342 | April 6, 2039 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | Aug. 29, 2022 | NEW CHEMICAL ENTITY |
| 1GM/VIAL;1GM/VIAL | VABOMERE | REMPEX | N209776 | Aug. 29, 2017 | RX | POWDER | INTRAVENOUS | Aug. 29, 2027 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-lactamase | Enzyme | Ki | 7.25 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 1C75676F8V | UNII |
| 4036930 | VANDF |
| C4519317 | UMLSCUI |
| CHEBI:755318 | CHEBI |
| 4D6 | PDB_CHEM_ID |
| CHEMBL3317857 | ChEMBL_ID |
| 56649692 | PUBCHEM_CID |
| DB12107 | DRUGBANK_ID |
| D10998 | KEGG_DRUG |
| 10182 | INN_ID |
| C000626994 | MESH_SUPPLEMENTAL_RECORD_UI |
| C000599945 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10871 | IUPHAR_LIGAND_ID |
| 737669009 | SNOMEDCT_US |
| 33058 | MMSL |
| d08644 | MMSL |
| 017323 | NDDF |
| 1945213 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VABOMERE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70842-120 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | NDA | 29 sections |